Quick Read – Falling prescription prices dragged Walmart’s U.S. comparable sales down 80 to 90 basis points, masking what would otherwise have been roughly 3.4% growth. – Target’s 3.8% comparable sales outpaced Walmart’s 2.6% because it sold its pharmacy business to CVS for $1.9…
llion in 2015, sidestepping drug-price deflation entirely. – Walmart’s transaction growth slowed to 1.5% from 3%, signaling lower-income shoppers are making fewer trips even as higher-income consumers trade down to Walmart. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Walmart didn’t make the cut. Grab the names FREE today
Walmart (NYSE:WMT) delivered the kind of quarter that should have been an easy win. Revenue rose 5.9% to $187.9 billion, topping Wall Street’s $186.8 billion estimate, and management raised its full-year sales and profit outlook. Yet the stock fell after investors focused on a troubling figure: U.S. comparable sales grew just 2.6%, a rare miss for a retailer that has consistently delivered stronger growth.
The obvious explanation is that consumers are running out of money. Walmart is where shoppers go when budgets tighten, so weaker sales could suggest even value-conscious households are feeling squeezed. But Target (NYSE:TGT) complicates that argument.